Betty Diamond

Affiliations: 
Yeshiva University, New York, NY, United States 
Area:
Immunology, Microbiology Biology
Google:
"Betty Diamond"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kurata-Sato I, Mughrabi IT, Rana M, et al. (2024) Vagus nerve stimulation modulates distinct acetylcholine receptors on B cells and limits the germinal center response. Science Advances. 10: eadn3760
Ramirez De Oleo I, Kim V, Atisha-Fregoso Y, et al. (2023) Phenotypic and functional characteristics of murine CD11c+ B cells which is suppressed by metformin. Frontiers in Immunology. 14: 1241531
Barlev AN, Malkiel S, Kurata-Sato I, et al. (2022) FcɣRIIB regulates autoantibody responses by limiting marginal zone B cell activation. The Journal of Clinical Investigation
Avancena P, Song T, Yao Y, et al. (2021) The magnitude of germinal center reactions is restricted by a fixed number of preexisting niches. Proceedings of the National Academy of Sciences of the United States of America. 118
Atisha-Fregoso Y, Toz B, Diamond B. (2021) Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. The Journal of Clinical Investigation. 131
Rana M, La Bella A, Lederman R, et al. (2021) Follicular dendritic cell dysfunction contributes to impaired antigen-specific humoral responses in sepsis-surviving mice. The Journal of Clinical Investigation
Bocharnikov AV, Keegan J, Wacleche VS, et al. (2019) PD-1hi CXCR5- T peripheral helper cells promote B cells responses in lupus via MAF and IL-21. Jci Insight
Arazi A, Rao DA, Berthier CC, et al. (2019) The immune cell landscape in kidneys of patients with lupus nephritis. Nature Immunology
Suurmond J, Atisha-Fregoso Y, Barlev AN, et al. (2019) Patterns of ANA+ B cells for SLE patient stratification. Jci Insight. 4
Teng YKO, Bruce IN, Diamond B, et al. (2019) Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. Bmj Open. 9: e025687
See more...